Altre lingue InnoCare Pharma Limited

Azioni

9969

KYG4783B1032

Tempo differito Hong Kong S.E. Altri mercati azionari 08:15:16 02/05/2024			Variaz. 5gg	Var. 1 gen.
5,16 ^HKD	+11,45%		+22,27%	-25,11%

29/03	InnoCare Pharma annuncia il dosaggio del primo paziente nello studio clinico della combinazione dell'inibitore SHP2 ICP-189 e dell'inibitore EGFR Furmonertinib	CI
28/03	Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	29/03
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China	13/03
InnoCare to Shrink Loss in 2023	29/01
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023	29/01
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China	24/01
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program	22/01
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA	16/01
InnoCare Elects CFO	18/12
InnoCare Pharma Provides Results of Phase 2 Trial for Atopic Dermatitis Medication; Shares Rise 4%	18/12
InnoCare Pharma Appoints Xin Fu as Chief Financial Officer	18/12
InnoCare Pharma Limited Announces the Positive Top-Line Results from the Phase II Randomized, Double-Blind, Placebo-Controlled Study of ICP-332	17/12
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH	11/12
InnoCare Pharma Logs 109 Million Yuan Loss in Q3	14/11
InnoCare Pharma Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	13/11
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China	27/10/23
Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director	11/10/23
RemeGen Names CFO	28/09/23
InnoCare Pharma Limited(SHSE:688428) added to Shanghai Stock Exchange Composite Index	26/09/23
InnoCare Pharma Limited(SHSE:688428) added to Shanghai Stock Exchange A Share Index	26/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue InnoCare Pharma Limited

Azioni

9969

KYG4783B1032

Altre lingue

Filtri